Scancell (LON:SCLP) Stock Price Down 3.2% - Here's Why

Key Points

• Scancell Holdings plc's shares fell by 3.2% on Tuesday, trading at GBX 9.69 after closing at GBX 10.
• The company has a notable debt-to-equity ratio of -566.79 and a market capitalization of £100.51 million.
• Insider Martin Diggle purchased 102,236 shares at an average price of GBX 11, reflecting a continuing insider interest in the company.

Shares of Scancell Holdings plc (LON:SCLP - Get Free Report) were down 3.2% on Tuesday . The company traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). Approximately 1,336,894 shares traded hands during mid-day trading, an increase of 44% from the average daily volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Stock Performance

The stock has a 50 day moving average price of GBX 10.15 and a two-hundred day moving average price of GBX 9.62. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The company has a market cap of £92.09 million, a price-to-earnings ratio of -426.63 and a beta of 0.35.

Insider Transactions at Scancell

In other news, insider Martin Diggle bought 4,400,000 shares of the stock in a transaction on Friday, August 1st. The stock was purchased at an average price of GBX 10 per share, for a total transaction of £440,000. Company insiders own 15.15% of the company's stock.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.